— Shares of biopharmaceutical company AbbVie shed more than 1% after the CEO said at the JPMorgan Healthcare Conference that it expects the loss of exclusivity of Humira, its drug for
arthritis and psoriasis, to affect the company's performance in the near term, according to a report from Bloomberg. The company does not anticipate a decline in 2024 earnings, however.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and moreThese are the stocks posting the largest moves midday.
La source: CNBC - 🏆 12. / 72 Lire la suite »
UBS sees these retail stocks winning from a potential Bed Bath & Beyond bankruptcyDoubts about Bed Bath & Beyond's future opens a door for other retailers to pick up market share, says UBS
La source: CNBC - 🏆 12. / 72 Lire la suite »
Bed Bath & Beyond jumps 50% to lead last gasp rally in meme stocks; AMC gains 15%A group of highly speculative stocks rallied double digits on Wednesday as retail investors pushed meme names up again in the new year following a dismal 2022.
La source: CNBC - 🏆 12. / 72 Lire la suite »